Wanbang Pharmaceutical Holding Group (002082.SZ) issues a pre-announcement, with a net profit of 65 million to 90 million yuan for 2024, representing an increase of 32.09% to 82.89%.

Wanbang Pharmaceutical Holding Group (002082.SZ) released its annual performance forecast for 2024, with an expected net profit attributable to shareholders of the listed company of 65-90 million yuan, a year-on-year increase of 32.09%-82.89%. The main reasons affecting the company's performance change during the reporting period are as follows: 1. During the reporting period, the company increased its efforts in the collection of accounts receivable, leading to a decrease in credit impairment provision compared to the same period last year. 2. During the reporting period, the company's subsidiary in South Africa further optimized its operation system, actively took measures to increase market share, and significantly improved its profitability. 3. During the reporting period, the company's subsidiary's real estate assets were confiscated by the government, leading to an increase in asset disposal income compared to the same period last year.